INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Company) promoted Glenn Coleman, to assume oversight of the
international business, effective December 1, 2016. Mr. Colemans
oversight of the international business will be in addition to his
current role as Corporate Vice President, Chief Financial Officer
and Principal Accounting Officer.
Financial Officer and Principal Accounting Officer since
2014.>Mr. Coleman has over 25 years in financial management
positions with leading global businesses. Prior to joining the
Company May 2, 2014, from 2008 to May 2014, Mr. Coleman served as
Vice President Finance, Corporate Controller at Curtiss-Wright
Corporation, a $2.5 billion global company headquartered in
Charlotte, North Carolina that delivers highly-engineered, critical
function products and services to the commercial, industrial,
defense and energy markets. Prior to joining Curtiss-Wright in
2008, Mr. Coleman worked at Alcatal-Lucent from 1997 to 2007, in
various finance executive leadership positions, including Vice
President for the Wireless and Wireline Business Groups, Controller
for the Americas region, Vice President of Internal Audit and
Finance Director of External and Internal Reporting. Mr. Coleman
was also instrumental in several significant corporate strategic
projects at Alcatel-Lucent, including a multi-billion-dollar
restructuring program, spin-off of an $8 billion publicly traded
entity, and numerous acquisitions. Prior to that, Mr. Coleman began
his career at PricewaterhouseCoopers LLP where he was the lead
Senior Manager for a top global account. Mr. Coleman received his
B.S. degree from Montclair State University and has also been a CPA
in New Jersey for more than 20 years.>
requiring disclosure under Item 401(d) or Item 404(a),
respectively, of Regulation S-K.
Directors (the Board) of the Company approved incentives in
connection with Mr. Colemans promotion detailed in a summary of
the promotion (the Coleman Promotion), which became effective
December 1, 2016, and provides for, among other things, the
following: (i) an increase in Mr. Colemans annual base salary
from $480,000 to $525,000 effective December 1, 2016, and (ii) a
short-term incentive target of seventy-five percent (75%) of his
base salary (an increase of 15% ) effective for the 2017 plan
year.
soon as administratively possible, of an award valued at $350,000
in the form of stock options as of the grant date of December 1,
2016 (the Grant Date) which shall vest on the third anniversary
of the Grant Date.>
President, Orthopedics and Tissue Technologies (OTT)
serve as Corporate Vice President and President, Orthopedics and
Tissue Technologies, effective December 1, 2016.
experience in the global healthcare industry. Mr. Davis joined
Integra in July 2012 as President of the Global Neurosurgery
business, and was appointed Integra’s Corporate Vice President in
December 2012 and President – Specialty Surgical Solutions in 2014.
Prior to joining Integra, Mr. Davis was the General Manager for the
Global Anesthesia Critical Care business at Baxter Healthcare, from
2009 to 2012, and held various general management positions at GE
Healthcare in the areas of interventional therapeutics,
cardiovascular imaging and diagnostic ultrasound, from 1997 to
2009. Mr. Davis earned his B.S. in Sports Medicine from the
University of Delaware, a Master’s degree in Exercise
Cardiovascular Physiology from Temple University, and an M.B.A.
from Drexel University.
requiring disclosure under Item 401(d) or Item 404(a),
respectively, of Regulation S-K.
connection with Mr. Daviss promotion detailed in a summary of the
promotion (the Davis Promotion), which became effective December
1, 2016, and provides for, among other things, the following: (i)
an increase in Mr. Daviss annual base salary from $401,500 to
$430,000
his base salary (an increase of 10%) effective for the 2017 plan
year.
as administratively possible, of an award valued at $200,000 in
the form of stock options as of the Grant Date which shall vest
on the third anniversary of the Grant Date.>>
not complete and is subject to and qualified in its entirety by the
terms of the summary of each promotion, a copy of which is filed
herewith as Exhibit 10.1 and 10.2, respectively, and incorporated
herein by reference.
change effective December 1, 2016, in a press release which is
included in this Current Report on Form 8-K as Exhibit 99.1 under
Item 9.01.
|
10.1
|
Coleman Promotion Summary, effective December 1, 2016
|
|
10.2
|
Davis Promotion Summary, effective December 1, 2016
|
|
99.1
|
Press Release dated December 5, 2016
|
About INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART)
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities. INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART) Recent Trading Information
INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART) closed its last trading session 00.00 at 75.78 with 608,917 shares trading hands.
